NK:IO, an Imperial College spinout, is revolutionising cancer treatment by harnessing the body's innate immune system. The platform, developed from groundbreaking NK cell research by Professors Hugh J. M. Brady and Matthew Fuchter, produces highly potent NK cells while overcoming traditional manufacturing hurdles.